2型糖尿病肾病患者血糖波动与肾功能和氧化应激的相关性分析

doi:10.3760/cma.j.issn.1007-1245.2022.23.010

摘要/Abstract

摘要： 目的　探讨2型糖尿病肾病患者血糖波动与肾功能和氧化应激的相关性分析。方法　选取2019年1月至2022年1月济南市第二人民医院收治的2型糖尿病患者82例，其中单纯2型糖尿病28例（单纯2型糖尿病组）、2型糖尿病肾病54例（2型糖尿病肾病组），另选取17例健康者为健康组。单纯2型糖尿病组患者中，男14例，女14例，年龄31~68（49.52±8.52）岁，吸烟5例；2型糖尿病肾病组患者中，男33例，女21例，年龄30~70（50.52±8.61）岁，吸烟3例；健康组中男10例，女7例，年龄30~80（52.52±8.77）岁，吸烟3例；收集研究对象的临床资料，比较3组研究对象的血糖波动指标（24 h平均血糖标准差、平均血糖波动幅度），采用全自动生化分析仪测定肾功能尿素氮（BUN）、肌酐（SCr），比较3组患者氧化应激活性氧（ROS）、超氧化物歧化酶（SOD）水平。采用t、χ²检验和单因素方差分析，采用Pearson法分析2型糖尿病肾病患者血糖波动与肾功能和氧化应激的相关性。结果　与健康组相比，单纯2型糖尿病组、2型糖尿病肾病组患者24 h平均血糖标准差、平均血糖波动幅较高（F=26.446、49.198，均P<0.001），2型糖尿病肾病组高于单纯2型糖尿病组，两组比较差异有统计学意义（均P<0.05）。与健康组相比，单纯2型糖尿病组、2型糖尿病肾病组患者BUN、SCr较低（F=17.541、16.524，均P<0.001），2型糖尿病肾病组低于单纯2型糖尿病组（均P<0.05）。与健康组相比，单纯2型糖尿病组、2型糖尿病肾病组患者ROS、SOD较低（F=21.250、18.522，均P<0.001），2型糖尿病肾病组低于单纯2型糖尿病组（均P<0.05）。Pearson结果显示，BUN、SCr、ROS、SOD与2型糖尿病肾病平均血糖波动幅度呈负相关（r=-0.365、-0.687、-0.854、-0.257，P=0.012、0.021、0.015、0.010）。结论　2型糖尿病肾病患者血糖波动与肾功能和氧化应激呈现负相关。

关键词: 2型糖尿病, 肾功能, 尿素氮, 肌酐, 氧化应激, 活性氧, 超氧化物歧化酶

Abstract: Objective　To explore the correlations of blood glucose fluctuation with renal function and oxidative stress in patients with type 2 diabetes nephropathy. Methods　Eighty-two patients with type 2 diabetes treated at Jinan Second People's Hospital from January 2019 to January 2022 were divided into a simple type 2 diabetes group (28 cases) and a type 2 diabetes nephropathy group (54 cases); 17 healthy people were selected as a healthy group. The clinical data were collected and compared. In the simple type 2 diabetes group, there were 14 males and 14 females who were 31-68 (49.52±8.52) years old, with 5 smokers. In type 2 diabetes nephropathy group, there were 33 males and 21 females who were 30-70 (50.52±8.61) years old, with 3 smokers. In the healthy group, there were 10 males and 7 females who were 30-80 (52.52±8.77) years old, with 3 smokers. The 24 h mean blood glucose standard deviations and mean blood glucose fluctuation ranges of the three groups were compared. The blood urea nitrogen (BUN) and creatinine (SCr) were measured by the automatic biochemical analyzer. The levels of reactive oxygen species (ROS) and superoxide dismutase (SOD) of the three groups were compared. t and χ² tests and one-way ANOVA were applied. The Pearson method was used to analyze the correlations of blood glucose fluctuation with renal function and oxidative stress in the patients with type 2 diabetes nephropathy. Results　The 24 h mean blood glucose standard deviations and the mean blood glucose fluctuation ranges in the simple type 2 diabetes group and the type 2 diabetes nephropathy group were higher those in the healthy group (F=26.446 and, 49.198, both P<0.001), and those in the type 2 diabetes nephropathy group were higher than those in the simple type 2 diabetes group, with statistical significance (both P<0.05). The BUN and SCR in the simple type 2 diabetes group and the type 2 diabetes nephropathy group were lower than those in the healthy group (F=17.541 and 16.524, both P<0.001), and those in the type 2 diabetes nephropathy group were lower than those in the simple type 2 diabetes group (both P<0.05). The ROS and SOD in the simple type 2 diabetes group and the type 2 diabetes nephropathy group were lower than those in the healthy group (F=21.250 and 18.522, both P<0.001), and the levels in the type 2 diabetes nephropathy group were lower than those in the simple type 2 diabetes group (both P<0.05). Pearson's results showed that BUN, SCR, ROS, and SOD were negatively correlated with the mean blood glucose fluctuation of the patients with type 2 diabetes nephropathy (r=-0.365, -0.687, -0.854, and -0.257; P= 0.012, 0.021, 0.015, and 0.010). Conclusion　There are negative correlations of blood glucose fluctuation with renal function and oxidative stress in patients with type 2 diabetes nephropathy.

Key words: Type 2 diabetes nephropathy, Renal function, Blood urea nitrogen, Creatinine, Oxidative stress, Reactive oxygen species, Superoxide dismutase

张娜刘梅嵇高德杨明鞠瀚. 2型糖尿病肾病患者血糖波动与肾功能和氧化应激的相关性分析[J]. 国际医药卫生导报, 2022, 28(23): 3296-.

Zhang Na, Liu Mei, Ji Gaode, Yang Ming, Ju Han. Correlations of blood glucose fluctuation with renal function and oxidative stress in patients with type 2 diabetes nephropathy[J]. International Medicine and Health Guidance News, 2022, 28(23): 3296-.

参考文献

[1] 肖英,栾森.血管紧张素Ⅱ受体1和二肽肌肽酶1基因多态性与糖尿病慢性肾脏疾病的相关性研究[J].中国糖尿病杂志,2015,23(6):497-500.DOI:10.3969/j.issn.1006-6187. 2015.06.005.
[2] 冯松青,赵佩英,吴琦.扫描式葡萄糖监测系统联合谷赖胰岛素治疗新诊断2型糖尿病患者血糖的临床观察[J].中国医药指南,2020,18(16):59-61. DOI: 10.15912/j.cnki.gocm.2020.16.025.
[3] 曹惠红.2型糖尿病患者血糖波动与血清胱抑素C的相关性研究[D]. 苏州:苏州大学,2018.
[4] Haas AV, Rosner BA, Kwong RY, et al. Sex differences in coronary microvascular function in individuals with type 2 diabetes[J]. Diabetes, 2019,68(3):631-636. DOI: 10.2337/db18-0650.
[5] Peters TM, Holmes MV, Richards JB, et al. Sex differences in the risk of coronary heart disease associated with type 2 diabetes: a mendelian randomization analysis[J]. Diabetes Care, 2021,44(2):556-562. DOI: 10.2337/dc20-1137.
[6] Noren Hooten N, Evans MK. Extracellular vesicles as signaling mediators in type 2 diabetes mellitus [J]. Am J Physiol Cell Physiol, 2020, 318(6):C1189-C1199.DOI:10.1152/ajpcell.00536.2019
[7] Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease[J]. Circ Res, 2020,126(11):1526-1548. DOI: 10.1161/CIRCRESAHA.119.316065.
[8] 贾伟平. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华医学会糖尿病学分会, 2019, 10(1):4-8.DOI:10.3760/cma.j.cn115791-20210706-00369
[9] Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke[J]. Diabetes, 2021,70(2):627-637. DOI: 10.2337/db20-0800.
[10] Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial[J]. Circulation, 2019,140(21):1693-1702. DOI: 10.1161/CIRCULATIONAHA. 119.042375.
[11] Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the american heart association[J]. Circulation, 2020,141(19):e779-e806. DOI: 10.1161/CIR. 0000000000000766.
[12] Hoseini A, Namazi G, Farrokhian A, et al. The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease[J]. Food Funct, 2019,10(9):6042-6051. DOI: 10.1039/c9fo01075k.
[13] Patsouras A, Farmaki P, Garmpi A, et al. Screening and risk assessment of coronary artery disease in patients with type 2 diabetes: an updated review[J]. In Vivo, 2019,33(4):1039-1049. DOI: 10.21873/invivo.11572.
[14] Ben Ahmed H, Bouzid K, Allouche E, et al. Relationship between Galectin-3 levels and severity of coronary artery disease in ST elevation myocardial infarction [J]. Tunis Med, 2020, 98(7):567-572.
[15] Yamamoto H, Shinke T, Otake H, et al. Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy [J]. J Diabetes Investig, 2021, 12(6):1015-1024. DOI:10.1111/jdi.13448.
[16] Wang R, Wang X, Zhang E, et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease [J]. Am J Transl Res, 2021, 13(8):8997-9004.
[17] Gong YY, Peng HY. Correlation analysis of epicardial adipose tissue thickness, C-reactive protein, interleukin-6, visfatin, juxtaposed with another zinc finger protein 1, and type 2 diabetic macroangiopathy[J]. Lipids in Health and Disease, 2021, 20(1):25.DOI:10.1186/s12944-021-01451-7.
[18] Hu Z, Yang M, Xie C, et al. Efficacy and safety of shenqi compound for the treatment of diabetic macroangiopathy: a protocol for systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(15):e19682. DOI: 10.1097/MD.0000000000019682.
[19] Gupta C, Bubber P, Fahim M, et al. Adiponectin in onset and progression of T2DM with cardiac dysfunction in rats[J]. Hum Exp Toxicol, 2020, 39(11):1463-1474. DOI: 10.1177/0960327120927446.
[20] Khandaker GM, Zuber V, Rees JMB, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort[J]. Mol Psychiatry, 2020,25(7):1477-1486. DOI: 10.1038/s41380-019-0395-3.
[21] Pinto LC, Rados DV, Remonti LR, et al. Patient-centered management of type 2 diabetes mellitus based on specific clinical scenarios: systematic review, meta-analysis and trial sequential analysis[J]. J Clin Endocrinol Metab, 2020, 105(11):dgaa534. DOI: 10.1210/clinem/dgaa534.
[22] 王惠,朱颖逸,董璐,等.基于Cite Space国内外糖尿病运动研究热点的可视化分析[J].国际医药卫生导报,2021,27(15):2216-2222.DOI:10.3760/cma.j.issn.1007-1245.2021. 15.001.
[23] Talari HR, Tabatabaei SMH, Soleimani A, et al. The effects of melatonin administration on carotid intima-media thickness and pulse wave velocity in diabetic nephropathy: a randomized, double-blind, placebo-controlled trial[J]. Clin Nutr ESPEN, 2022, 48:82-86. DOI: 10.1016/j.clnesp.2022.01.002.
[24] Yang T, Heng C, Zhou Y, et al. Corrigendum to 'Targeting mammalian serine/threonine-protein kinase 4 through yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis [Metabolism Clinical and Experimental 108 (2020) 154258][J]. Metabolism, 2022, 130:154963. DOI: 10.1016/j.metabol.2021.154963.
[25] Wen Y, Liu Y, Huang Q, et al. Corrigendum to "Moringa seed extract protects kidney function in rats with diabetic nephropathy by increasing GSK-3β activity and activating the Nrf2/HO-1 pathway" [Phytomedicine 95 (2022) 153856][J]. Phytomedicine, 2022, 100:154043. DOI: 10.1016/j.phymed.2022.154043.
[26] Carmona M, Paco-Meza LM, Ortega R, et al. Hypoxia preconditioning increases the ability of healthy but not diabetic rat-derived adipose stromal/stem cells (ASC) to improve histological lesions of streptozotocin-induced diabetic nephropathy[J]. Pathol Res Pract, 2022, 230:153756. DOI: 10.1016/j.prp.2021.153756.
[27] Jin J, Wang Y, Zheng D, et al. A novel identified circular RNA, mmu_mmu_circRNA_0000309, involves in germacrone-mediated improvement of diabetic nephropathy through regulating ferroptosis by targeting miR-188-3p/GPX4 signaling axis[J]. Antioxid Redox Signal, 2022, 36(10-12):740-759. DOI: 10.1089/ars.2021.0063.